Kwang Dong Pharmaceutical Co., Ltd. (009290.KS)
KRW 5670.0
(0.0%)
KRW 5670.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 36.96 Billion KRW | 52.91% |
| 2022 | 24.17 Billion KRW | 0.64% |
| 2021 | 24.01 Billion KRW | -47.06% |
| 2020 | 45.36 Billion KRW | 96.76% |
| 2019 | 23.05 Billion KRW | 3.19% |
| 2018 | 22.34 Billion KRW | -3.67% |
| 2017 | 23.19 Billion KRW | -17.34% |
| 2016 | 28.06 Billion KRW | -19.86% |
| 2015 | 35.01 Billion KRW | -0.08% |
| 2014 | 35.04 Billion KRW | 59.02% |
| 2013 | 22.03 Billion KRW | -20.8% |
| 2012 | 27.82 Billion KRW | -7.02% |
| 2011 | 29.92 Billion KRW | 18.68% |
| 2010 | 25.21 Billion KRW | 8.75% |
| 2009 | 23.18 Billion KRW | 8.31% |
| 2008 | 21.4 Billion KRW | -11.4% |
| 2007 | 24.16 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 1.32 Billion KRW | -92.73% |
| 2024 Q1 | 18.2 Billion KRW | 228.93% |
| 2023 FY | 36.96 Billion KRW | 52.91% |
| 2023 Q4 | 5.53 Billion KRW | -37.34% |
| 2023 Q3 | 8.83 Billion KRW | 3.19% |
| 2023 Q2 | 8.55 Billion KRW | -39.07% |
| 2023 Q1 | 14.04 Billion KRW | 96.54% |
| 2022 Q1 | 7.58 Billion KRW | 15.18% |
| 2022 Q2 | 3 Billion KRW | -60.46% |
| 2022 FY | 24.17 Billion KRW | 0.64% |
| 2022 Q3 | 6.44 Billion KRW | 114.69% |
| 2022 Q4 | 7.14 Billion KRW | 10.94% |
| 2021 Q3 | 8.94 Billion KRW | 282.41% |
| 2021 Q1 | 6.15 Billion KRW | 190.62% |
| 2021 Q2 | 2.33 Billion KRW | -62.0% |
| 2021 FY | 24.01 Billion KRW | -47.06% |
| 2021 Q4 | 6.58 Billion KRW | -26.33% |
| 2020 Q2 | 10.96 Billion KRW | 2.61% |
| 2020 Q3 | 30.51 Billion KRW | 178.39% |
| 2020 Q1 | 10.68 Billion KRW | 334.07% |
| 2020 FY | 45.36 Billion KRW | 96.76% |
| 2020 Q4 | -6.79 Billion KRW | -122.25% |
| 2019 Q1 | 9.11 Billion KRW | 434.09% |
| 2019 Q3 | 4.09 Billion KRW | -44.52% |
| 2019 FY | 23.05 Billion KRW | 3.19% |
| 2019 Q4 | 2.46 Billion KRW | -39.93% |
| 2019 Q2 | 7.38 Billion KRW | -18.97% |
| 2018 Q2 | 4.82 Billion KRW | -33.48% |
| 2018 Q3 | 8.54 Billion KRW | 77.04% |
| 2018 Q4 | 1.7 Billion KRW | -80.04% |
| 2018 FY | 22.34 Billion KRW | -3.67% |
| 2018 Q1 | 7.25 Billion KRW | 156.32% |
| 2017 Q1 | 6.3 Billion KRW | 197.56% |
| 2017 Q4 | 2.83 Billion KRW | -72.36% |
| 2017 Q3 | 10.24 Billion KRW | 168.77% |
| 2017 FY | 23.19 Billion KRW | -17.34% |
| 2017 Q2 | 3.81 Billion KRW | -39.5% |
| 2016 Q2 | 9.6 Billion KRW | 20.42% |
| 2016 Q3 | 8.36 Billion KRW | -12.85% |
| 2016 Q4 | 2.11 Billion KRW | -74.69% |
| 2016 FY | 28.06 Billion KRW | -19.86% |
| 2016 Q1 | 7.97 Billion KRW | 33.41% |
| 2015 Q4 | 5.97 Billion KRW | -40.43% |
| 2015 FY | 35.01 Billion KRW | -0.08% |
| 2015 Q3 | 10.03 Billion KRW | -9.43% |
| 2015 Q2 | 11.07 Billion KRW | 39.75% |
| 2015 Q1 | 7.92 Billion KRW | 3.53% |
| 2014 Q3 | 11.29 Billion KRW | 20.93% |
| 2014 Q2 | 9.33 Billion KRW | 38.22% |
| 2014 FY | 35.04 Billion KRW | 59.02% |
| 2014 Q1 | 6.75 Billion KRW | 26.66% |
| 2014 Q4 | 7.65 Billion KRW | -32.2% |
| 2013 Q3 | 10.25 Billion KRW | 1370.77% |
| 2013 Q4 | 5.33 Billion KRW | -48.01% |
| 2013 FY | 22.03 Billion KRW | -20.8% |
| 2013 Q1 | 5.74 Billion KRW | -10.31% |
| 2013 Q2 | 697.57 Million KRW | -87.86% |
| 2012 Q2 | 7.22 Billion KRW | 30.75% |
| 2012 Q3 | 8.16 Billion KRW | 13.05% |
| 2012 Q4 | 6.4 Billion KRW | -21.53% |
| 2012 FY | 27.82 Billion KRW | -7.02% |
| 2012 Q1 | 5.52 Billion KRW | 0.0% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q2 | 8.83 Billion KRW | 43.43% |
| 2011 Q3 | 7.79 Billion KRW | -11.71% |
| 2011 Q1 | 6.15 Billion KRW | 5.95% |
| 2011 FY | 29.92 Billion KRW | 18.68% |
| 2010 Q3 | 7.78 Billion KRW | 10.63% |
| 2010 Q2 | 7.03 Billion KRW | 53.74% |
| 2010 Q1 | 4.57 Billion KRW | -23.25% |
| 2010 Q4 | 5.81 Billion KRW | -25.34% |
| 2010 FY | 25.21 Billion KRW | 8.75% |
| 2009 FY | 23.18 Billion KRW | 8.31% |
| 2009 Q4 | 5.96 Billion KRW | -24.05% |
| 2009 Q3 | 7.85 Billion KRW | 56.03% |
| 2009 Q1 | 4.33 Billion KRW | 45.5% |
| 2009 Q2 | 5.03 Billion KRW | 16.08% |
| 2008 Q3 | 8.75 Billion KRW | 81.11% |
| 2008 Q2 | 4.83 Billion KRW | -0.03% |
| 2008 FY | 21.4 Billion KRW | -11.4% |
| 2008 Q4 | 2.97 Billion KRW | -65.97% |
| 2008 Q1 | 4.83 Billion KRW | -23.0% |
| 2007 Q4 | 6.28 Billion KRW | -21.28% |
| 2007 Q2 | 5.82 Billion KRW | 42.81% |
| 2007 Q1 | 4.07 Billion KRW | 0.0% |
| 2007 FY | 24.16 Billion KRW | 0.0% |
| 2007 Q3 | 7.97 Billion KRW | 36.98% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 614.776% |
| Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | 36.255% |
| Ildong Holdings Co., Ltd. | -59.58 Billion KRW | 162.036% |
| HANDOK Inc. | -28.79 Billion KRW | 228.364% |
| Kukje Pharma Co., Ltd. | -8.41 Billion KRW | 539.272% |
| Yuhan Corporation | 93.5 Billion KRW | 60.469% |
| Dong-A ST Co., Ltd. | 11.12 Billion KRW | -232.35% |
| SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | 248.982% |
| Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | 74.721% |
| Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | -953.568% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 1574.839% |
| Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | 1882.41% |
| MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | 916.948% |
| Hana Pharm Co., Ltd. | 22.33 Billion KRW | -65.522% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 614.776% |
| Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | 276.523% |
| REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | -931.586% |
| Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 131.255% |
| JW Holdings Corporation | 19.02 Billion KRW | -94.287% |
| Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | 146.834% |
| Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 82.606% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 0.11% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 164.484% |
| Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | -503.839% |
| Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | -2122.103% |
| Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | -638.61% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 614.776% |
| Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | 66.848% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 0.11% |
| Yuhan Corporation | 93.5 Billion KRW | 60.469% |
| Jeil Pharma Holdings Inc | -16.24 Billion KRW | 327.484% |
| Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | 1053.816% |
| Suheung Co., Ltd. | 6.11 Billion KRW | -504.089% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 0.11% |
| Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | -95.525% |
| Korea United Pharm Inc. | 48.26 Billion KRW | 23.406% |
| CKD Bio Corp. | -24.19 Billion KRW | 252.797% |
| Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | -54.558% |
| Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | -34.723% |
| Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | -24.152% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 164.484% |
| Chong Kun Dang Holdings Corp. | 47 Billion KRW | 21.362% |
| Boryung Corporation | 40.2 Billion KRW | 8.052% |
| Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | 217.989% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 1574.839% |
| JW Lifescience Corporation | 28.14 Billion KRW | -31.345% |